Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with Keytruda (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
RAHWAY, N.J.--(BUSINESS WIRE) April 4, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 4, 2024 Category: Pharmaceuticals Source Type: clinical trials
Multiple Risk Factor Intervention Trial (Ms. FIT)
Conditions: Metabolic Disturbance; Sedentary Behavior Interventions: Behavioral: Behavioural Experimental: guidelines-based physical activity; Behavioral: Behavioural Experimental: guidelines-based physical activity and healthy eating; Behavioral: Behavioural: Stretching exercise Sponsors: University of Toronto; Canadian Institutes of Health Research (CIHR) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
Cessation of Somatostatin Analogues After PRRT in Mid-Gut Neuroendocrine Tumours
Conditions: Neuroendocrine Tumors Interventions: Drug: Cessation of somatostatin analogues; Drug: Continuation of somatostatin analogues Sponsors: Australasian Gastro-Intestinal Trials Group; Canadian Cancer Trials Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
Early Detection of Liver Cancer by QUS
Conditions: Hepatocellular Carcinoma; Liver Cancer Interventions: Diagnostic Test: Quantitative Ultrasound; Diagnostic Test: B-mode Ultrasound; Diagnostic Test: Magnetic Resonance Imaging; Diagnostic Test: Liver Biopsy Sponsors: Centre hospitalier de l ' Universit é de Montréal (CHUM); Centre de Recherche du Centre Hospitalier de l ' Universit é de Montréal; Canadian Institutes of Health Research (CIHR) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients With Platinum-Resistant Ovarian Cancer
BASKING RIDGE, N.J.& RAHWAY, N.J., April 3, 2024– Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the first patient has been dosed in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 3, 2024 Category: Pharmaceuticals Source Type: clinical trials
A Novel Iron-Based Supplement for Athletes Aged 14-17
Conditions: Iron Deficiencies Interventions: Other: FeSC Sponsors: University of Calgary; Mitacs; Natural Sciences and Engineering Research Council, Canada Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
Real-World Effectiveness of Mavacamten in Canada
Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM) Interventions: Drug: Mavacamten Sponsors: Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials
Role of Active Deresuscitation After Resuscitation:
Conditions: Fluid Overload; Critical Illness; Sepsis; ARDS; Trauma Interventions: Drug: Furosemide Injection; Drug: Metolazone Tablets Sponsors: Unity Health Toronto; Canadian Institutes of Health Research (CIHR) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2024 Category: Research Source Type: clinical trials
The IMPACT Implementation-Effectiveness Trial
Conditions: Cancer Interventions: Behavioral: Exercise; Behavioral: Self-management e-module Sponsors: McMaster University; Canadian Cancer Society (CCS); Hamilton Health Sciences Corporation; Niagara Health System Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 21, 2024 Category: Research Source Type: clinical trials
Maitake for Integrative Cancer Care
Conditions: Cancer Interventions: Dietary Supplement: Black Maitake Prothera Sponsors: The Canadian College of Naturopathic Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 21, 2024 Category: Research Source Type: clinical trials
Effect of Dairy Product Matrices on Insulin Resistance in People With Overweight and Obesity and Prediabetes
Conditions: PreDiabetes; Overweight and Obesity Interventions: Other: 250 mL serving size, 3.25% fat content; Other: 175 g serving size, ≥2% fat content; Other: 50 g serving size, ≥28% fat content Sponsors: McGill University Health Centre/Research Institute of the McGill University Health Centre; Dairy Farmers of Canada Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 21, 2024 Category: Research Source Type: clinical trials
Technology in Play for Children With Physical Disabilities: the Dice Model of Play
Conditions: Physical Disability Interventions: Other: robots; Other: conventional Sponsors: University of Manitoba; Rehabilitation Centre for Children, Canada Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2024 Category: Research Source Type: clinical trials
Emergency Medicine Pulmonary Embolism Testing Multicentre Study
Conditions: Pulmonary Embolism; D-dimer; Diagnosis Interventions: Diagnostic Test: Adjust-Unlikely Sponsors: Dr. Kerstin de Wit; Canadian Institutes of Health Research (CIHR) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2024 Category: Research Source Type: clinical trials
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
RAHWAY, N.J.--(BUSINESS WIRE) March 19, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive data from multiple Phase 3 studies evaluating V116, the company’s investigational,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 19, 2024 Category: Pharmaceuticals Source Type: clinical trials
